Company Filing History:
Years Active: 2022
Title: Jiwen Xu: Innovator in PPAR Agonist Development
Introduction
Jiwen Xu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biochemistry, particularly in the development of pharmaceutical compounds. His innovative work focuses on the creation of novel compounds that can have therapeutic applications.
Latest Patents
Jiwen Xu holds a patent for an "Amorphous pyrrolidine derivative as PPAR agonist and preparation method thereof." This invention relates to a unique amorphous pyrrolidine derivative that acts as a PPAR agonist, which is crucial for various biological processes. The preparation method outlined in the patent provides a new approach to synthesizing this compound, potentially leading to advancements in drug development.
Career Highlights
Jiwen Xu is currently associated with Guangdong Raynovent Biotech Co., Ltd. His role in the company allows him to apply his expertise in biochemistry and contribute to innovative research and development projects. His work has garnered attention in the scientific community, showcasing his commitment to advancing medical science.
Collaborations
Jiwen Xu collaborates with notable colleagues, including Zhiliang Yuan and Zhigan Jiang. These partnerships enhance the research environment and foster innovation within the company.
Conclusion
Jiwen Xu's contributions to the field of biochemistry, particularly through his patent on PPAR agonists, highlight his role as an influential inventor. His work continues to pave the way for new therapeutic developments in medicine.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.